Cargando…
Preference of acromegaly patients for treatment attributes in Spain
OBJECTIVE: Acromegaly is a rare disease caused by increased growth hormone secretion and a subsequent increase in insulin-like growth factor I (IGF-I) levels. Patients display multiple comorbidities that affect their quality of life (QoL). Treatment aims to maintain good biochemical control, tumour...
Autores principales: | Fajardo, Carmen, Álvarez-Escola, Cristina, Biagetti, Betina, Garcia-Centeno, Rogelio, Ciriza, Raquel, Sánchez-Cenizo, Laura, Díaz-Muñoz, Marcos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543785/ https://www.ncbi.nlm.nih.gov/pubmed/37507554 http://dx.doi.org/10.1007/s12020-023-03462-z |
Ejemplares similares
-
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
por: de Pablos-Velasco, Pedro, et al.
Publicado: (2019) -
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
por: Biagetti, Betina, et al.
Publicado: (2022) -
Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study
por: Marazuela, Mónica, et al.
Publicado: (2021) -
Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021) -
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)